Lowe Brockenbrough & Co. Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,921 shares of the company’s stock after purchasing an additional 2,076 shares during the quarter. Johnson & Johnson accounts for about 1.9% of Lowe Brockenbrough & Co. Inc.’s investment portfolio, making the stock its 8th biggest holding. Lowe Brockenbrough & Co. Inc.’s holdings in Johnson & Johnson were worth $13,095,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of JNJ. Financial Gravity Wealth Inc. purchased a new stake in Johnson & Johnson during the first quarter valued at $105,000. WP Advisors LLC purchased a new stake in Johnson & Johnson during the second quarter valued at $108,000. FNY Investment Advisers LLC purchased a new stake in Johnson & Johnson during the second quarter valued at $117,000. Fusion Family Wealth LLC increased its position in Johnson & Johnson by 621.4% during the second quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock valued at $123,000 after acquiring an additional 870 shares during the last quarter. Finally, Live Your Vision LLC increased its position in Johnson & Johnson by 58.3% during the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after acquiring an additional 502 shares during the last quarter. Hedge funds and other institutional investors own 66.51% of the company’s stock.
A number of analysts recently commented on JNJ shares. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Tuesday, November 20th. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Sunday, October 14th. Citigroup upped their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price objective on shares of Johnson & Johnson in a research report on Friday, September 14th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $143.90.
NYSE:JNJ opened at $145.43 on Friday. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. The stock has a market cap of $391.46 billion, a price-to-earnings ratio of 18.35, a P/E/G ratio of 2.28 and a beta of 0.59.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business had revenue of $20.35 billion during the quarter, compared to analyst estimates of $20.05 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 8.16 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a yield of 2.48%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 49.32%.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 8,441 shares of the business’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the completion of the sale, the chief accounting officer now owns 17,284 shares of the company’s stock, valued at $2,508,772.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joaquin Duato sold 40,000 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $144.36, for a total value of $5,774,400.00. Following the sale, the insider now directly owns 112,848 shares of the company’s stock, valued at approximately $16,290,737.28. The disclosure for this sale can be found here. Insiders have sold 510,544 shares of company stock valued at $74,414,877 in the last three months. 0.22% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) is Lowe Brockenbrough & Co. Inc.’s 8th Largest Position” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/12/08/johnson-johnson-jnj-is-lowe-brockenbrough-co-inc-s-8th-largest-position.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Featured Story: How to Invest in Growth Stocks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.